Perusahaan Gas Negara (PGN), a unit of Indonesian state-owned oil and gas company Pertamina, said it will buy some LNG ...

While PepGen works to persuade the FDA to let it launch a phase 2 trial of its Duchenne muscular dystrophy (DMD) therapy in ...

The Boston-based company has filed with the US Securities and Exchange Commission ... the clinical development of lead oligonucleotide PGN-EDO51 for DMD, as well as two other oligo drugs PGN ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...

PepGen has shared positive initial data from its ongoing FREEDOM-DM1 Phase I trial, which is evaluating PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1). In the 5mg/kg and 10mg/kg dose ...

Sultan Shakir, president and executive officer of the Mazzoni Center, has announced his resignation from the LGBTQ+ health ...

This will allow us to gather additional safety data, assess the impact of this dose of PGN-EDO51 on dystrophin levels, and potentially improve the design of CONNECT2,” said James McArthur ...